Phase II study demonstrates value of uPAR-PET in head
her kan det potensielt komme flere gode nyheter fremover, men en dyktig ledelse.
“We are excited about the positive data from the phase II study in head and neck cancer using the uTRACE® technology that has been published by researcher from Rigshospitalet. First and foremost, the results underscore that uPAR-PET is a platform technology that can be used across several cancer types. Furthermore, we do not only expect uTRACE® to be valuable for planning of therapy and follow-up, but it may also become a companion diagnostic for use of uTREAT® in head and neck cancer. Curasight will now take the published information into consideration when updating our strategy over the next months. However, with head and neck cancer being a common cancer type, the market potential of moving into this indication is obviously very large.” says CEO Ulrich Krasilnikoff.
“We are excited about the positive data from the phase II study in head and neck cancer using the uTRACE® technology that has been published by researcher from Rigshospitalet. First and foremost, the results underscore that uPAR-PET is a platform technology that can be used across several cancer types. Furthermore, we do not only expect uTRACE® to be valuable for planning of therapy and follow-up, but it may also become a companion diagnostic for use of uTREAT® in head and neck cancer. Curasight will now take the published information into consideration when updating our strategy over the next months. However, with head and neck cancer being a common cancer type, the market potential of moving into this indication is obviously very large.” says CEO Ulrich Krasilnikoff.